Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 9/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 9/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.35 |
| ▸ | CHRNB3 | Q05901 | 7/20 | 0.35 |
| ▸ | CHRNA6 | Q15825 | 7/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26498812 | 0.83 | HRH3 (0.45) | HRH3DPP8DPP7SIGMAR1 | |
| SCHEMBL17816044 | 0.79 | CHRNB2 (0.50) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL25075302 | 0.79 | HRH3 (0.44) | HRH3MEN1KMT2ADPP8DPP7 | |
| SCHEMBL25480245 | 0.78 | HRH3 (0.44) | HRH3CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL17815918 | 0.78 | CHRNB2 (0.37) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL2737380 | 0.76 | — | — | |
| SCHEMBL25489003 | 0.76 | HRH3 (0.54) | HRH3DPP8DPP7HSD11B1SIGMAR1 | |
| SCHEMBL18294315 | 0.76 | HPGD (0.52) | HRH3MEN1KMT2ACHRNA7HSD11B1 | |
| SCHEMBL26421320 | 0.75 | HRH3 (0.42) | HRH3CHRNB2CHRNA3CHRNA4CHRNB3 | |
| SCHEMBL14804490 | 0.73 | HRH3 (0.48) | HRH3DPP8DPP7HSD11B1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | NURIX THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158151-A1 | COMPOUNDS FOR INHIBITING OR DEGRADING TARGET PROTEINS, COMPOSITIONS, COMPRISING THE SAME, METHODS OF THEIR MAKING, AND METHODS OF THEIR USE | MDM2, XIAP, ADRM1 | HRH3 3926/4885CHRNB2 4318/4885CHRNA3 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.